Dr. Sohal on Perioperative mFOLFIRINOX in Pancreatic Adenocarcinoma
Davendra Sohal, MD, MPH
Davendra Sohal, MD, MPH, Department of Hematology and Medical Oncology, Cleveland Clinic, discusses an ongoing study exploring mFOLFIRINOX versus gemcitabine and nab-paclitaxel (Abraxane) in patients with resectable pancreatic adenocarcinoma.
SWOG S1505 is one of the first cooperative group studies exploring this treatment in pancreatic cancer, Sohal explains. It is a shift from the standard of care for these patients, which is surgery followed by adjuvant chemotherapy with or without radiation therapy. However, research now shows that pancreatic cancer is a systemic disease and it should be targeted with aggressive systemic chemotherapy regimens upfront.
This is what this study is testing, Sohal adds—the efficacy, safety, and feasibility of this approach.